Big Pharma Can’t Own a Natural Peptide. So What Are They Patenting?

A pharmaceutical company can spend a decade and billions of dollars developing a peptide drug, and still not own the actual molecule nature already invented. That’s not a loophole. It’s the law working exactly as designed, and understanding why explains a surprising amount about how the entire peptide drug industry is actually structured.

The rule: you can’t patent what nature already made

Under U.S. patent law, a product that exists in nature generally cannot be patented simply because someone found it, isolated it, or purified it. This is sometimes called the product of nature doctrine, and the Supreme Court reinforced it directly in two major decisions. In Mayo Collaborative Services v. Prometheus Laboratories (2012), the Court held that a law of nature combined with routine, conventional steps isn’t enough to clear the patent eligibility bar. In Association for Molecular Pathology v. Myriad Genetics (2013), the Court ruled that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, while synthetic cDNA, which does not occur naturally in that form, can be patented. Both cases dealt with genes rather than peptides directly, but they established the same underlying principle that governs peptide patents too: discovering something nature already built is not, on its own, an invention.

So what does a peptide drug patent actually protect

If the natural sequence itself is off the table, the actual intellectual property in a peptide drug has to live somewhere else, and it typically lives in four places.

Engineered modifications. A native peptide hormone is often unstable, broken down by the body within minutes. Drug developers make targeted changes, a single amino acid substitution, an attached fatty acid chain, a modified backbone, specifically to extend how long the molecule survives in circulation. These modifications are novel, human-designed structures distinct from the natural molecule, and they’re squarely patentable.

Methods of manufacture. How a peptide is synthesized, purified, and produced at scale is its own separate intellectual property. Two companies can both work with a similar underlying peptide structure and still hold entirely different, both valid, patents on how they actually make it.

Delivery systems. An injection pen engineered for once-weekly dosing, a formulation designed to survive stomach acid for an oral version, an absorption enhancer that lets a peptide cross the gut wall intact, all of these are patentable inventions layered on top of the underlying molecule.

Specific use claims. A patent can cover a particular therapeutic use of a compound for a defined condition, even when the molecule itself, or a closely related version of it, has other unprotected uses or exists in other contexts.

Why the price gap makes more sense once you see this

This is also why a peptide drug can be extraordinarily expensive to develop and defend legally while the natural hormone it’s based on remains, in principle, unownable. The commercial value was never really in the raw sequence. It’s in the engineering that made an unstable, minutes-long natural signal into something that survives a week in the body, in the manufacturing process that produces it reliably at scale, in the delivery mechanism that gets it into a patient’s system, and in the specific, clinically validated use it’s been proven to serve.

None of that diminishes what the natural molecule does on its own, inside the body, the way it’s done for millions of years before any of this patent architecture existed. It just explains why the patent sitting on top of it looks nothing like the molecule itself.

References

Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).

Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).